1 Vane JR, Bakhle YS, Bot ting RM.Cy clooxyg e nases 1 and 2 Annu.Rev.Pharmacol Toxicol;1998; 38:97
2 Lane NE.Pain managementin osteoarth ritis:therole ofCOX-2 inhibitor s.J Rheumatol, 1997;2 4(Suppl 49): 20
3 Kaw amori T, Rao CV, Seiber t K, et al.Chemopre-ventive activity of celecoxib, a spe cific cyclooxyg e-nase-2 inhibitor, against colon carcinog enesis.Cancer Res, 1998;58(3):4 091
4 Hamilton LC, Mitchell JA, Tomlinson AM, et al. Syner gy be twe en cyclo-oxyg enase-2 induction and arachidonic acid supply in vivo:consequence s for nonsteroidal antiinflamma tor y drug efficacy.FASEB J, 1999;1 3(2):2 45
5 M ande ll BF, Cle ve.COX-2 selective NSAIDs:biolo-gy, promises, and concerns.Clin J Med, 1999;66(5):2 85
6 M cAdam BF, Catella-Law son F,M ardini IA, et al. Sy stemic biosyn thesis of prostacyclin by cyclo-oxyg enase COX-2:the human pharmacology of a selective inhibitorof COX-2.Proc Na tl Acad Sci, 1999;96(1):272
7 Simon LS, Lanza FL, Lipsky PE, et a l.Preliminary study of the safety and efficacyof SC-58635, a nove l cyclooxygenase-2 inhibitor:efficacyand safety in twoplacebo-controlled trials in osteoart hritis and rheumato id arthritis, and studies of gastrointestinal and platelet effects.Art hritis Rheum, 1998;41(9): 1591
8 Lipsky PE.Role of cyclooxyg enase-1 and-2 in health and disease.Am J Or thop, 1999;28(3 Suppl):8
9 Lipsky PE, Isakson PC.Outcomeof specific COX-2 inhibition in rheumatoid arthritis.J Rheumatol, 1997;(24 Suppl 49):9
10 Fort J.Celecoxib, a COX-2 spe cific inhibitor:the clinical da ta.Am J Or thop, 1999;28(3 Suppl):1 3
11 Gierse JK, Koboldt CM,Walker MC, et a l.Kinetic basis for selective inhibition of cyclo-oxygenase s. Biochem J, 1999;3 39(Pt 3):6 07 |
